Health Canada issues contrasting agent advisory
Health Canada has notified Canadian hospitals about safety concerns over contrast agents containing gadolinium which are used primarily in MRIs and have been linked to a condition called nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy, or NSF/NFD. To date, 109 cases of NSF/NFD associated with gadolinium-containing contrast agents have been reported worldwide, although none has been reported in Canada. So far, NSF/NFD has been observed only in patients with serious kidney disease, Health Canada said yesterday in an advisory.
Continue reading "Health Canada issues contrasting agent advisory" »
